Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "MD"

1661 News Found

India to import 450,000 vials of Remdesivir
News | May 01, 2021

India to import 450,000 vials of Remdesivir

The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country


Govt. approves 25 manufacturing sites for Remdesivir production
News | April 26, 2021

Govt. approves 25 manufacturing sites for Remdesivir production

The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month


COVID-19 drug Remdesivir now priced at Rs. 899
News | March 25, 2021

COVID-19 drug Remdesivir now priced at Rs. 899

Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.


FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
News | February 07, 2026

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy


Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
News | February 07, 2026

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing


Apotex scores exclusive Canadian rights to testosterone therapy Nebido
News | February 07, 2026

Apotex scores exclusive Canadian rights to testosterone therapy Nebido

Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada


Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
News | February 07, 2026

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades